Molecular Basis of Pediatric Liver Cancer
Genetic and Molecular Basis of Pediatric Liver Cancer
1 other identifier
observational
1,600
1 country
1
Brief Summary
The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 22, 2015
CompletedFirst Submitted
Initial submission to the registry
May 15, 2019
CompletedFirst Posted
Study publicly available on registry
May 22, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2029
September 12, 2025
September 1, 2025
13 years
May 15, 2019
September 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Gene sequencing
DNA sequence variants
Recurrence free survival at 2 years
Gene expression analysis
Differentially expressed genes
Recurrence free survival at 2 years
Status of genome-wide chromatin accessibility
chromatin accessibility
Duration of active chemotherapy to two years after surgical treatment
Epigenetic change
Differential methylation
Duration of active chemotherapy to two years after surgical treatment
Tumor infiltrating cells which express immune checkpoints
differentially enriched immune cells
Duration of active chemotherapy to two years after surgical treatment
Secondary Outcomes (2)
Response to chemotherapy
Duration of active chemotherapy to two years after surgical treatment
Response to chemotherapy
Duration of active chemotherapy to two years after surgical treatment
Eligibility Criteria
Living or deceased individuals who were diagnosed with a liver tumor, malignant or benign, during childhood (age \<21 years) and their biological parents and siblings.
You may qualify if:
- Prior or current treatment for a childhood liver tumor, malignant or benign, at age \<21 years.
- Biological parents and siblings of eligible children.
You may not qualify if:
- No prior or current treatment for a childhood liver tumor.
- Non-biological parents, legal guardians, or non-biological siblings of eligible children.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
Biospecimen
Samples with DNA: blood, saliva or liver tissue.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Surgery
Study Record Dates
First Submitted
May 15, 2019
First Posted
May 22, 2019
Study Start
June 22, 2015
Primary Completion (Estimated)
June 30, 2028
Study Completion (Estimated)
June 30, 2029
Last Updated
September 12, 2025
Record last verified: 2025-09